论文部分内容阅读
[目的]观察参芪复方对2型糖尿病(T2DM)脂代谢异常的影响并探讨其作用机制。[方法]按血糖值高低随机分为模型组,雷米普利组[0.45mg/(kg·d)],参芪复方低、高剂量组[0.504g/(kg·d)与2.002g/(kg·d)]及Wistar对照组,给药30d。用葡萄糖氧化酶法、酶免法及生化检测法等测定大鼠空腹血糖(FPG)、血清氧化修饰低密度脂蛋白(ox-LDL)、血脂及游离脂肪酸(FFA)。[结果]参芪复方高剂量组FPG、FFA、ox-LDL及血脂水平显著低于模型组(P<0.05或P<0.01)。[结论]参芪复方能够改善其血脂紊乱状态,并有一定降糖作用。
[Objective] To observe the effect of Shenqi compound on abnormal lipid metabolism in type 2 diabetes (T2DM) and explore its mechanism of action. [Methods] According to the level of blood glucose levels were randomly divided into model group, Ramipril group [0.45mg/(kg·d)], Shenqi compound low and high dose group [0.504g/(kg·d) and 2.002g/ (kg·d)] and Wistar control group were administered for 30 days. Fasting glucose (FPG), serum oxidized low-density lipoprotein (ox-LDL), serum lipids and free fatty acids (FFA) were determined by glucose oxidase method, enzyme-free method and biochemical assay. [Results] The FPG, FFA, ox-LDL and blood lipid levels of Shenqi compound high-dose group were significantly lower than the model group (P<0.05 or P<0.01). [Conclusion] Shenqi compound can improve the status of dyslipidemia and have certain hypoglycemic effect.